8-K 1 v242971_8k.htm CURRENT REPORT ON FORM 8-K Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 8, 2011
 
WaferGen Bio-systems, Inc.
(Exact name of registrant as specified in its charter)

Nevada
  
000-53252
  
90-0416683
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(I.R.S. Employer
Identification No.)
 
7400 Paseo Padre Parkway
Fremont, CA  94555
  
94555
(Address of principal executive offices)
  
(Zip Code)


Registrant’s telephone number, including area code: (510) 651-4450

Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 

Item 7.01.  Regulation FD Disclosure.

On December 8, 2011, WaferGen Bio-systems, Inc.  (the “Company”) issued a press release announcing it will participate in the Oppenheimer 22nd Annual Healthcare Conference in New York, at the Waldorf-Astoria Hotel, on Tuesday, December 13, 2011 at 3:35 p.m. Eastern Time.  This presentation may be accessed by the public via live webcast at www.wafergen.com. The webcast will be archived until March 12, 2012. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1, and the slide show presented by the Company is attached hereto as Exhibit 99.2.
 
The information in this Current Report on Form 8−K, including Exhibits 99.1and 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as we may specifically state in any such filing.


Item 9.01. Financial Statements and Exhibits.
 
(d) 
Exhibits.
 
Exhibit No.
  
Description
99.1
  
Press release issued on December 8, 2011.
99.2
  
Slide show to be presented at Oppenheimer 22nd Annual Healthcare Conference

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  WaferGen Bio-systems, Inc.  
     
       
Date: December 13, 2011
By:
/s/ Don Huffman  
   
Don Huffman
   
Office of the President and Chief Financial Officer
       
 
 
2